---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-087903"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:32:26.414603+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pasithea activates two South Korean sites for PAS-004 NF1 trial; first patient dosed

## Summary
- Two sites activated: Asan Medical Centre and Severance Hospital Yonsei University Health System, both now recruiting.
- First patient in South Korea dosed; trial enrolling Cohort 2 (8 mg tablet) after SRC cleared Cohort 1 without modification.
- Initial interim clinical data from first two cohorts expected in Q1 2026.
- Phase 1/1b study of PAS-004 (macrocyclic MEK inhibitor) in adult NF1 patients with symptomatic plexiform neurofibromas.
- Trial also includes sites in Australia and U.S.; Part A dose escalation (4 mg to 18 mg) identifying recommended Part B dose.

## SEC filing metadata
- accession: 0001213900-25-087903
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390025087903/0001213900-25-087903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390025087903/ea0257501-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-087903
- JSON: https://secwatch.observer/filing/0001213900-25-087903.json
- Plain text: https://secwatch.observer/filing/0001213900-25-087903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.